Indian drugmaking major Sun Pharmaceutical faces potential impact from US' 100% tariffs on patented drugs, which could reduce its FY26 and FY27 earnings by 8–10%, HSBC reported. This comes as Sun Pharmaceutical is the only Indian company with significant stake in patented drugs in US. The tariff, which excludes companies building manufacturing plants in US, won't apply to generic medicines.